Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McDonald's Corp (MCD) vs TransMedics Group Inc (TMDX) Price & Performance

McDonald's CorpTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

McDonald's Corp vs TransMedics Group Inc — how do they compare? McDonald's Corp trades at $273.87 (market cap $193.70B), while TransMedics Group Inc trades at $89.86 (market cap $3.07B). The key difference: McDonald's Corp is far larger — about 63.1× TransMedics Group Inc's market cap, and McDonald's Corp pays a 2.72% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

MCDTMDX
Market Cap
$193.70B$3.07B
Volume
2,230,036
Sector
Consumer CyclicalTechnology
52-Week High
$341.06$150.42
52-Week Low
$262.80$61.99
Enterprise Value
$247.47B$3.46B
Dividend Yield
2.72%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McDonald's Corp

McDonald's (MCD) trades at $274.15, down slightly by 0.12% on the day, with technical indicators showing a neutral overall signal. The company demonstrates strong fundamentals with consistent revenue growth, reaching $26.89 billion in 2025, and robust profitability with a 31.72% net income margin. Recent earnings have consistently beaten expectations, and the company has announced a new global growth strategy focused on automation and menu innovation to drive future performance.

The outlook for MCD is positive, supported by strong analyst consensus with a $322.45 price target implying significant upside. Key opportunities include the successful execution of its new growth plan and its defensive qualities in a challenging economy. Primary risks involve inflationary pressures on franchisee margins and intense competition in the quick-service restaurant sector.

TransMedics Group Inc

TMDX trades at $83.89, up 4.59% today, with a bullish technical signal from moving averages and strong support at $81. The company reported a Q2 2026 earnings miss ($0.44 actual vs. $0.50 expected) but beat revenue expectations, with 2025 net income at $190.29M. Analyst consensus is a Buy with a $99.57 price target, though recent news highlights a legal investigation into fiduciary duties.

Outlook remains positive due to raised revenue guidance and institutional interest, but risks include earnings volatility, margin pressure, and legal scrutiny. The stock's valuation multiples suggest growth expectations, yet execution on cost control and international expansion will be critical for sustained upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About McDonald's Corp

McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.

Read more on MCD

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX